Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).
Over the last 20 years the treatment of cutaneous T-cell lymphoma has been in a state of continual change. New therapies are constantly emerging as the search continues for more effective and tolerable disease-specific agents that satisfy medical needs. Therapies under investigation include topical retinoids, fusion molecules like denileukin diftitox, pegylated interferon, interleukin-2, and interleukin-12. Pegylated liposomal doxorubicin, gemcitabine, and chlorodeoxyadenosine also appear to have clinical potential. Other identified agents include vaccines and monoclonal antibodies. This article reviews some of the most recent clinical innovations.
Dummer
Reinhard
R
Department of Dermatology, University Hospital of Zurich, Switzerland. reinhard.dummer@usz.ch
D000256:Adenoviridae / Q000235:genetics; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005544:Forecasting; D015316:Genetic Therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000628:therapy*; D011701:PUVA Therapy; D012176:Retinoids / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D012176:Retinoids; D007372:Interferons